1-2 of 2
Jeffrey L. Brown
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Free
Jeffrey L. Brown, Z. Alexander Cao, Maria Pinzon-Ortiz, Jane Kendrew, Corinne Reimer, Shenghua Wen, Joe Q. Zhou, Mohammad Tabrizi, Steve Emery, Brenda McDermott, Lourdes Pablo, Patricia McCoon, Vahe Bedian, David C. Blakey
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 145–156.
https://doi.org/10.1158/1535-7163.MCT-09-0554
Published: 12 January 2010
View article titled, A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
Open the PDF for A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

Free
Kenneth Thress, Terry MacIntyre, Haiyun Wang, Dave Whitston, Zhong-Ying Liu, Ethan Hoffmann, Tao Wang, Jeffrey L. Brown, Kevin Webster, Charles Omer, Peter E. Zage, Lizhi Zeng, Patrick A. Zweidler-McKay
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (7): 1818–1827.
https://doi.org/10.1158/1535-7163.MCT-09-0036
Published: 14 July 2009
View article titled, Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Open the PDF for Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway in another window
Includes: Supplementary data